Empagliflozin improves left ventricular ejection fraction and end systolic volume in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD trial

ConclusionEmpagliflozin can have cardioprotective benefits in subjects without HF. Further studies are required to determine the effect of Empagliflozin in non-HF patients.Trial registrationThe original EMPA-CARD study has been registered in Iranian Registry of Clinical Trials.www.IRCT.ir, Identifier: IRCT20190412043247N2. Registration Date: 6/13/2020. Registration timing: prospective.
Source: Journal of Diabetes and Metabolic Disorders - Category: Endocrinology Source Type: research